FHL2 anticorps

N° du produit ABIN265171

Détail du produit anti-FHL2 anticorps

Antigène: FHL2 (Four and A Half LIM Domains 2 (FHL2))

Reactivité: Humain

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp FHL2 est non-conjugé

Application: Western Blotting (WB)

Purification: Purified

Immunogène: Synthetic peptide derived from the human FHL2 protein

Isotype: IgG

Information d'application

Indications d'application: Western Blot: (0.5-2 μg/mL).
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Buffer: Phosphate buffered saline with 0.08 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: -20 °C

Stockage commentaire: Store the product (in aliquots) at -20 °C. Can be shipped at 2 - 8 °C.

Détails sur FHL2

Antigène: FHL2 (Four and A Half LIM Domains 2 (FHL2))

Autre désignation: FHL2 / SLIM3 (FHL2 Produits)

Synonymes: anticorps AAG11, anticorps DRAL, anticorps FHL-2, anticorps SLIM-3, anticorps SLIM3, anticorps C76204, anticorps FHL2, anticorps zgc:92428, anticorps zgc:103466, anticorps four and a half LIM domains 2, anticorps four and a half LIM domains 2a, anticorps four and a half LIM domains 2b, anticorps FHL2, anticorps Fhl2, anticorps fhl2, anticorps fhl2a, anticorps fhl2b

Sujet: Sphingosine kinase-1 (SK1) is a key enzyme that catalyzes the phosphorylation of sphingosine to sphingosine-1-phosphate (S1P). SK1, and its product S1P, regulate numerous and diverse biological functions, including cell growth, differentiation, proliferation, and apoptosis. S1P also plays a central role in cardiac development and ischemic preconditioning. FHL2 (SLIM3) has been identified as a SK1-interacting protein in mammalian cardiomyocytes. FHL2, but not FHL1 or FHL3, interacts with SK1, and FHL2 colocalizes with SK1 in the cytoplasm of these cells. The interaction of FHL2 with SK-1 involves the C-terminal portion of SK1. Overexpression of FHL2 has been found to attneuate the activity and antiapoptotic effects of SK1. Endothelin-1, a potent survival factor in cardiomyocytes, inhibits FHL2-SK1 association and increases SK1 activity. FHL2 is therefore a novel inhibitor of SK1 activity in cardiomyocytes and targeting FHL2 may prevent myocardial apoptosis through activation of SK1. A transcriptional coactivator, FHL2 is also known to form complexes consisting of Proline-, glutamic acid-, and leucine-rich protein-1 (PELP1), FHL2, and androgen receptors (AR) in prostate cancer cells, perhaps functioning as a molecular adaptor with PELP1 in the progression of prostate cancer.Synonyms: DRAL, FHL-2, Four and a half LIM domains protein 2, LIM domain protein DRAL, SLIM 3, Skeletal muscle LIM-protein 3

ID gène: 9606

UniProt: Q14192

Pathways: Intracellular Steroid Hormone Receptor Signaling Pathway, Regulation of Lipid Metabolism by PPARalpha